Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112353 · ClinicalTrials.gov registry record · Phase 4
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
A Phase 4 study of Intestinal Disease, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
- 1
- Study location
NCT06112353: Recruiting Phase 4 study of Intestinal Disease, sponsored by University of California, Irvine.
NCT06112353 is a Phase 4 study of Intestinal Disease that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 128 participants, below the 195-participant average among 3 other Intestinal Disease trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06112353, a Phase 4 study of Intestinal Disease, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
Primary Outcome
GI-2 recovery as defined as hour to first bowel movement and toleration of oral diet
Conditions Studied
Interventions
- DRUG Neostigmine Injectable Solution
- DRUG Sugammadex injection
Study Locations (1)
California
- UC Irvine Medical Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
What NCT06112353 shows while recruiting
NCT06112353 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 195-participant average among 3 other Intestinal Disease trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Intestinal Disease appearing as the primary indexed condition, and to 2 interventions - of which Neostigmine Injectable Solution is the first listed.
NCT06112353 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06112353 about?
NCT06112353 is a clinical study titled "Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection". The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
What is the current status of trial NCT06112353?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2024-04-17. Estimated completion is 2026-07-31.
What conditions does trial NCT06112353 study?
This clinical trial studies the following conditions: Intestinal Disease.
What interventions are being tested in trial NCT06112353?
The interventions under investigation include: Neostigmine Injectable Solution (DRUG), Sugammadex injection (DRUG).
Who is sponsoring clinical trial NCT06112353?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112353 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intestinal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI